Results 81 to 90 of about 224,404 (241)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab

, 2009
Piet GeusensDepartment of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands and Biomedical Research Institute, University Hasselt, BelgiumAbstract: The pathway of the receptor activator of ...
Piet Geusens
core   +1 more source

Hormone Replacement Therapy for Menopausal Symptoms and the Risk of Cardiometabolic Disease: Current Evidence and Future Directions

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background The transition through menopause is accompanied by a series of adverse metabolic changes which are associated with an increased risk of cardiometabolic disease, a major cause of mortality in women after midlife. Whilst the indication for menopausal hormone replacement therapy (HRT) is the control of menopausal symptoms ...
Jiawen Dong, Sarah Hillman, Sharon Dixon, Anupa Shah, Radha Venkatakrishnan, Jeremy W. Tomlinson   +5 more
wiley   +1 more source

Osteoporosis and polymorphisms of osteoprotegerin gene in postmenopausal women – a pilot study

, 2016
Objectives: Osteoprotegerin (OPG) has an important role in bone remodeling, and it has been proposed that the OPG gene might be a candidate gene for osteoporosis predisposition.
Pasezada Kosovic, Selma Cvijetic, Tomislav Nemcic, Melita Uremovic, Jasminka Bobic, Simeon Grazio   +5 more
core   +1 more source

Indications and Efficacy of Progestogen‐Monotherapy as Menopause Hormone Therapy: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms (VMS) and other manifestations of menopause; however, its use is limited in women with contraindications to oestrogen. Progestogen monotherapy, though historically underutilized, represents a viable alternative in this population. This narrative review
Chloe Thomas, Olivia Carere, Lauren Clarfield, Michelle Jacobson   +3 more
wiley   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

Deciphering epigenetic regulation in postmenopausal osteoporosis: Current and future perspectives

View
Postmenopausal osteoporosis is the most prevalent form of osteoporosis, affecting approximately 33% of postmenopausal women globally and representing a major cause of age‐related disability and mortality.
Xiumei Tang, Meiru Chen, Guixuan Xu, Yuan Li, Sen Guo, Yufeng Huang, Zhaoliang Hou, Xiaoling Hou, Zhijian Wei, Wenzhao Wang, Bing Ning   +10 more
doaj   +1 more source

Osteoporosis self-assessment tool for Asians and calcaneal quantitative ultrasound for identifying primary osteoporosis in Taiwanese postmenopausal women

Frontiers in Endocrinology
ObjectivesThis study compares Osteoporosis Self-Assessment Tool for Asians (OSTA) and Calcaneal Quantitative Ultrasound (QUS) to detect primary osteoporosis among Taiwanese postmenopausal women and assess the consistency between both methods.Methods8,883
Dung-Huan Liu, Dung-Huan Liu, Dung-Huan Liu, Chih-Sheng Lin, Chih-Sheng Lin, Chih-Sheng Lin, Pei-Ching Wu, Pei-Ching Wu, Pei-Ching Wu   +8 more
doaj   +1 more source

The Effect of Continous or Intermittent Calcitonin in the Treatment of Postmenopausal Osteoporosis

, 2002
The aim of this study was to compare the efficacy of continuous and intermittent salmon calcitonin in the treatment of postmenopausal osteoporosis. Sixty-eight women with postmenopausal osteoporosis were randomized to 2 treatment groups. The first group
F. Taşçıoğlu, C. Öner, O. Armağan
core  

Current Pharmacological Approaches to Prevent and Treat Post-Menopausal Osteoporosis

, 2010
Osteoporosis characterized by low bone mass and structural deterioration of bone tissue; has a huge impact on public health through high morbidity, mortality and economic costs associated with resultant fractures.
YANG, RONG-SEN;LIU, SHING-HWA, 楊榮森;劉興華   +1 more
core   +1 more source

It's not “just aging”: Reframing postmenopausal urological dysfunction in primary care

UroPrecision, EarlyView.
Maya Aldeeb, Ibrahim A. Khalil
wiley   +1 more source